Microglia-targeted candidates push the Alzheimer drug envelope

Nature Reviews Drug Discovery 17, 303 (2018). doi:10.1038/nrd.2018.65 Author: Asher Mullard Denali Therapeutics is taking a swing at neuroinflammation with a first-in-man trial of a RIPK1 inhibitor, while the company and others search for ways to target microglial biology more precisely.
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: News and Analysis Source Type: research